Targeted alpha therapy: a new tool for advanced prostate cancer

The study by Mike M Sathekge and colleagues in The Lancet Oncology1 is the largest investigation to demonstrate the antitumour effect and toxicity of alpha-emitting Actinium-225 (225Ac) prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) in metastatic castration-resistant prostate cancer (mCRPC). Before this study, the largest published single institution experience had included 106 patients.2 Sathekge and colleagues1 now report 488 patients from countries in four continents: South Africa (n=248), Australia (n=57), India (n=111), and Germany (n=72).